FDA Grants Fast Track Designation for SNB-101 to Treat Small Cell Lung Cancer
The FDA has granted fast track designation for a polymer nanoparticle anticancer drug, SNB-101 (API: SN-38), to treat individuals with small cell lung cancer (SCLC). The study authors noted that SNB-101 was designated as an orphan drug for SCLC and …